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Refractory chronic GVHD (cGVHD) is an important
complication after allogeneic hematopoietic SCT and is
prognostic of poor outcome. MSCs are involved in tissue
repair and modulating immune responses in vitro and
in vivo. From April 2005 to October 2008, 19 patients
with refractory cGVHD were treated with MSCs derived
from the BM of volunteers. The median dose of MSCs
was 0.6 10
6 cells per kg body weight. Fourteen of 19
patients (73.7%) responded well to MSCs, achieving a CR
(n¼4) or a PR (n¼10). The immunosuppressive agent
could be tapered to less than 50% of the starting dose in 5
of 14 surviving patients, and ﬁve patients could discontinue
immunosuppressive agents. The median duration between
MSC administration and immunosuppressive therapy
discontinuation was 324 days (range, 200–550 days). No
patients experienced adverse events during or immediately
after MSC infusion. The 2-year survival rate was 77.7% in
this study. Clinical improvement was accompanied by the
increasing ratio of CD5þCD19þ/CD5 CD19þ B cells
and CD8þCD28 /CD8þCD28þ T cells. In conclusion,
transfusion of MSCs expanded in vitro, irrespective of the
donor, might be a safe and effective salvage therapy for
patients with steroid-resistant, cGVHD.
Bone Marrow Transplantation (2010) 45, 1732–1740;
doi:10.1038/bmt.2010.195; published online 6 September 2010
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Introduction
Chronic GVHD (cGVHD) is one of the main limitations to
successful allogeneic hematopoietic SCT, and has a
substantial impact not only on survival but also on the
quality of life of otherwise cancer-free patients. Half of the
patients undergoing a HLA-identical allograft who survive
beyond 100 days may require long-term immunosuppres-
sive treatment for extensive cGVHD, often for more than 2
years.
1–3 More than one-third of patients with cGVHD do
not respond to ﬁrst-line therapy, which often involves
combinations of corticosteroids and a calcineurin inhibi-
tor.
4 There is no standard second-line or salvage therapy
for these patients and they have a poor outcome.
5–11 MSCs
are multipotent non-hematopoietic stem cells that can
differentiate into various lineages and have been used to
repair injured tissues.
12–17 Recently, MSCs have also shown
unique immunomodulatory properties in vitro, including
inhibition of T-cell proliferation after stimulation by allo-
Ag and mitogens, and prevention of the activity of
cytotoxic T cells.
18,19 MSCs have been used for the
prophylaxis of acute GVHD
20 and for the treatment of
patients with steroid-refractory acute GVHD,
21–24 but just
one study has reported the temporary effect of MSCs in a
patient with refractory cGVHD.
22
In this study, we investigated the effects of MSCs derived
from HLA-identical sibling donors or HLA-disparate
third-party donors as a salvage therapy for 19 patients
with refractory cGVHD.
Patients and methods
Patient characteristics and deﬁnitions
Between April 2005 and October 2008, 19 patients were
treated with in vitro expanded BM-derived MSCs as a
compassionate treatment for refractory cGVHD (Table 1).
Patients included in this study require the presence of one
of the evidences: (1) the manifestations of cGVHD show
no improvement during treatment with the standard
immunosuppressive therapy, including corticosteroids and
calcineurin inhibitors or combination with other immuno-
suppressive agents after 1 month; (2) the manifestations of
cGVHD show evidence of progression after at least 2 weeks
of standard immunosuppressive therapy or during steroid
or other immunosuppressive agents taper. The study was
approved by the Ethics Committee of Guangdong General
Hospital. All patients and the MSC donors provided
written informed consent.
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All patients received sibling HLA-identical PBSCs after
treatment with ﬂudarabine combined with modiﬁed BU/
CY-conditioning regimes (FABC conditioning regimen),
which consisted of cytarabine 2.0g/m
2 on day  9, BU
3.2mg/kg per day for i.v. on days  8 to day 6, followed by
CY 60mg/kg per day on days  5 and day  4, combined
ﬂudarabin 30mg/m
2 per day for three consecutive days, on
days  6 to day  4, and Me-CCNU (1-(2-chloroethyl)-3-
(4-ethylnitrobiphenyl cylohexyl4)-1-nitrosourea) 250mg/m
2
on day  3. All patients received CsA in combination with a
short course of mycophenolate mofetil and four doses of
MTX for GVHD prophylaxis. The dosage of CsA was
2.0mg/kg per day i.v. from day 9 before transplantation
until bowel function was normal, at which time the patient
was switched to oral CsA according to the ratio of 1:2.5.
The dose of mycophenolate mofetil was 0.5g every
12h orally from day 9 before transplantation to day 1
before transplantation. The dose of MTX was 15mg/m
2 i.v.
on days þ1 (1 day after transplantation), then 10mg/m
2
i.v. on days þ3, þ6a n dþ11 after transplantation. Patients
received Pneumocystis carinii prophylaxis with trimethoprim/
sulfamethoxazole, antiviral prophylaxis with acyclovir or
equivalent, and antibacterial prophylaxis with penicillin or
equivalent.
HSC donors
All donors were HLA-identical siblings. HLA typing was
performed by genomic low-resolution DNA-based typing
(PCR sequence-speciﬁc primer).
Diagnosis and grading of GVHD
The diagnosis, organ scoring and global assessment of
cGVHD were based on the National Institutes of Health
(NIH) consensus criteria for cGVHD.
25 The onset forms of
cGVHD were determined according to the published
classiﬁcations.
26
Treatment prior to MSC administration
All patients except one had failed to respond to at least two
previous lines of immunosuppressive therapy more than 6
weeks before receiving MSCs (Table 2). The median time
from cGVHD diagnoses to MSC infusion was 35.6 weeks
(range, 6.4–246.1). One patient (UPN124732) suffered
moderate cGVHD that resolved with calcineurin inhibitor
and steroid, but recurred after discontinuing all agents 6
months later. This patient received MSC infusion only for
the treatment of cGVHD recurrence.
MSC preparation and administration
BM-derived MSCs were aspirated (20mL) under local
anesthesia from HLA-matched donors or HLA-disparate
third-party adult donors. This study was approved by the
institutional review board of the Guangdong General
Hospital, and all donors provided written informed
consent. Human MSCs were isolated and cultured as
previously described with minor modiﬁcations.
27,28 Brieﬂy,
20mL BM aspirates were diluted 1:1 with human MSC
growth medium (consisting of low glucose Dulbecco’s
modiﬁed Eagle’s medium (L-DMEM; Hyclone, Logan,
UT, USA) and 10% fetal bovine serum (FBS; Hyclone))
Table 1 Clinical characteristics of patients with refractory cGVHD and the organ response
UPN Sex Age
(years)
Disease Organ scoring before MSC and organ response
Skin Eyes Oral Liver GI Muscle Plt Lung
AB CA BC AB C AB C AB CA BC A BC A BC
102309 F 35 CML 3
a mPR PR — — — — — — 3 mPR CR — — — 2 NR PR — — — — — —
065877 F 39 ALL 2 PR CR 1 NR CR 3 CR CR — — — 2 CR CR — — — — — — — — —
125883 M 28 AML 3 PR GPR 2
b N R P R 3P RC R —— — —— —— —— — —— — ——
128497 M 33 AML 2 mPR CR 2
b NR PR 2 PR CR 2 NR CR — — — — — — — — — — — —
112707 M 22 AML 3 NR mPR 3
b PR PR 3 mPR PR 2 PR CR 3 PR PR — — — — — — — — PD
144925 M 26 CML 2 mPR CR 2 PR CR 2 PR CR 3 PR CR 2 PR CR — — — — — — — — —
152529 M 35 CML 3
a mPR mPR 1
b NR NR 2 CR CR — — — 3 GPR CR 2 NR PR — — — — — —
151639 M 36 AML 3 NR PR 2
b NR NR 3 PR PR — PR CR — — — — — — — — — — — —
157937 F 28 CML 3 PR PR 2
b NR PR 3 PR CR 2 NR CR — — — — — — — — — — — PD
202507 F 18 AML 2 PR PR 1
b NR NR 2 PR PR 2 CR CR 2 PR PR — — — — — — — — —
167290 M 19 ALL 3 PR PR 2
b NR PR 3 PR PR 1 CR CR 3 GPR GPR — — — — — — — — —
173264 M 28 CML 1 CR CR 1
b NR NR — — — 3 GPR CR — — — — — — — — — — — PD
206111 F 28 CML 2 PR PR 1
b NR NR 1 CR CR 2 NR NR — — — — — — — — — 3 NR NR
065877 M 33 AML 3
a NR NR 3
b NR NR 2 PR PR — — — 3 NR NR — — — — — — — — —
211188 M 36 CML 1 NR PR 1
b NR NR 2 CR CR — — — 1 CR CR 2 NR NR — — — — — —
120560 M 20 MDS 2 mPR mPR — — — — — — — — — 3 PR PR — — — 2 NR PR — — —
213198 M 35 ALL 2 PR PR 1 NR CR 2 PR PR 2 CR CR — — — — — — — — — — — —
124732 M 28 CML — — — 1
b NR NR 2 CR CR — — — — — — — — — — — — — — —
196003 M 31 ALL 2 PR PR 1
b NR NR 2 PR PR — — — 2 PR PR — — — 3 NR PR — — —
Abbreviations: A¼scoring before MSC treatment; B¼initial response; C¼ﬁnal response; cGVHD¼chronic GVHD; F¼female; GI¼gastrointestinal;
GPR¼good partial response; M¼male; MDS¼myelodysplastic syndrome; mPR¼minor partial response; NR¼no response; PD¼progressive disease or
emerge new involvement; UPN¼unique patient number.
aWith scleroderma.
bKeratoconjunctivitis sicca.
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Amersham Biosciences, Uppsala, Sweden). After centrifu-
gation at 800g for 20min, mononuclear cells were collected
from the interface, washed and resuspended in human
MSC growth medium at a density of 5000cells/cm
2. After 3
days, the non-adherent cells were removed by replacing the
spent medium with fresh medium. Adherent cells were
further cultured with media changes every 3 days. When
they were 70–80% conﬂuent, cells were detached by
trypsin-EDTA and passaged at a ratio of 1:3. Multiple
individual donor preparations were performed and second
or third passage MSCs were used for individual experi-
ments. All these samples have been tested for their ability to
differentiate into osteoblasts, adipocytes and chondrocytes.
Flow cytometry was performed using a FACSort and
analyzed with CellQuest software (Becton Dickinson, San
Jose, CA, USA). The culture-expanded cells expressed
CD29, CD44, CD73, CD90, CD105 and CD166, but not
CD11a, CD34 or CD45. They could be induced to
differentiate into cells of osteogenic, adipogenic and
chondrogenic lineages under proper induction medium
(Figure 1). The MSCs were screened negative for pathogens
and contaminants (for example, bacteria, fungi, virus,
mycoplasma and endotoxin) before infusion.
The planned MSC dose scheme was 1.0 10
6/kg body
weight, but there were some difﬁculties in growing sufﬁcient
MSCs on time for patient infusion as planned. As a result,
the median MSC dose given was 0.6 10
6/kg body weight
(range 0.23–1.42 10
6/kg per body weight). MSCs were
harvested fresh from culture and administered to the
patients by i.v. infusions over 30min. The median number
of MSC administrations was 2 (range, 1–5). The median
duration between the ﬁrst and second MSC application was
188 days (range, 13–944 days).
Evaluation of response and monitoring
Evaluation of response to cGVHD treatment is fairly
difﬁcult owing to the lack of uniform assessment criteria
and the various disease manifestations of this disease. In
this pilot study, we used the NIH consensus criteria for
organ scoring and global assessment of cGVHD
25 and
measures of assessing response.
29 Patients were evaluated at
3-month intervals after the ﬁrst MSC administration,
including scoring and the following domains were scored:
skin, oral mucosa, liver, gastrointestinal system, eyes,
muscle, joint, and lung. These domains were chosen to
make the evaluation as objective as possible. The patient
investigation form used to obtain information about
symptoms and the physician investigation form was
collected at each follow-up visit. A detailed symptom list
and physical examination ﬁndings were recorded, and these
two forms were used to conﬁrm responses. In the case of a
discrepancy, objective data, such as biological sign and
laboratory results, were used to clarify ambiguity. Each
patient’s response was assessed at 3 months and at his or
her ﬁnal assessment. The organ response and the overall
response were used to determine the therapeutic effects of
MSC for refractory cGVHD.
Assessment of organ response
According to the criteria of organ scoring proposed by
NIH for cGVHD,
29 each organ was assigned scores of 0
(none) to 3 (worst). The response deﬁnitions were in
agreement with current studies:
5,7,11,16 CR was deﬁned as
the resolution of all clinical manifestations of the involved
organ, except the irreversible injury (such as severe
scleroderma and keratoconjunctivitis sicca). Damage
caused to certain organs by cGVHD is not reversible or
Table 2 Immunosuppression and global response in patients with refractory chronic GVHD
UPN Immunosuppressive
agents before
MSC infusion
No. of
MSCs
Primary
response
Final
response
Immunosuppressive
agents at the last
follow-up
Outcome (no. of days of
follow-up) and disease status
at the last follow-up
PSL, mg/kg Other agent PSL (mg/kg) Other agents
102309 0.5 FK506 3 NR PR — — Alive (1823) in PR
065877 0.5 CsA/Penicillanmine/Thal 1 PR CR — — Alive (1375) in CR
125883 0.5 CsA/MMF 3 NR PR — CsA Alive (1367) in PR
128497 0.5 CsA/MMF/Thal 2 NR CR — — Alive (1210) in CR
112707 0.5 FK506/MMF 4 NR MR — FK506 Died (1083) in MR
144925 0.5 CsA 2 PR CR — — Alive (1013) in CR
152529 0.3 FK506/MTX/Azathioprine 5 NR PR — FK506/MTX Alive (922) in PR
151639 0.5 CsA/MTX 1 NR PR — CsA/MTX Alive (1073) in PR
157937 0.6 CsA/MTX 1 PR MR 0.3 — Alive (1040) in MR
202507 0.5 CsA/MTX 1 NR PR — CsA Died (331) in PR
167290 0.4 CsA 2 NR PR — FK506/MTX Died (763) in PR
173264 0.3 CsA/MMF 1 PR MR 0.5 — Alive (719) in MR
206111 1 CsA 2 NR NR — CsA Died (234) in NR
065877 0.3 MMF 2 NR NR 0.05 MMF Alive (2791) in NR
211188 0.5 FK506/Azathioprine 1 PR PR — FK506 Alive (546) in PR
120560 1 FK506/Budesonide 2 PR PR 0.1 FK506 Alive (711) in PR
213198 0.8 CsA 1 PR PR — CsA Died (261) in PR
124732 — — 1 PR CR — — Alive (1343) in CR
196003 1.6 CsA/MTX/Penicillanmine 3 NR PR 0.3 CsA/Penicillanmine Alive (511) in PR
Abbreviations: FK506¼tacrolimus; MMF¼mycophenolate mofetil; MR¼mixed response; NR¼no response; PSL¼prednisone; Thal¼thalidomide;
UPN¼ unique patient number.
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29,30 such as chronic dry eyes, esophageal stricture,
bronchiolitis obliterans, or advanced skin sclerosis or
contractures. To objectively assess the therapeutic response
of a novel salvaged treatment for refractory cGVHD, we
excluded ‘irreversible’ injuries of scleroderm and kerato-
conjunctivitis sicca from the CR to avoid bias of responses
assessment. Good PR (GPR) was deﬁned as reduction
in clinical manifestations and laboratory data of more
than 75% or improvement by more than one point on a
four-point scale without achieving CR; PR 10 was deﬁned
as improvement by at least one point in the involved organ,
or reductions in clinical manifestations and laboratory data
of more than 50% but less than 75%. Minor PR (mPR)
was deﬁned as improvement of less than one point in one
organ or clinical symptom score and reductions in
laboratory data of more than 25% but less than 50%.
Progressive disease (PD) was deﬁned as worsening in any
domain of at least 25% or deterioration of more than one
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Figure 1 Characterization and differentiation of human MSCs. (a) Phase-contrast microscopy of human MSCs at passage 3. (b) Alizarin red S staining of
osteogenic differentiated human MSCs. (c) Oil red O staining of adipogenic differentiated human MSCs. (d) Toluidine blue staining of chondrogenic
differentiated human MSCs. (e) Flow-cytometric analysis of cell surface Ags of human MSCs. Bar¼200mm.
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Bone Marrow Transplantationpoint while on treatment or steroid taper. No response
(NR) was deﬁned as no improvement or deterioration in
the affected organ. Each organ in cGVHD after MSC
infusion was estimated as showing meaningful response
(CR, GPR and PR), progression or NR. Patients with an
initial improvement but subsequent worsening were con-
sidered as showing disease recurrence.
Assessment of overall response
Patients were evaluated according to the NIH consensus
criteria of cGVHD,
29 and the grade was reassessed (none,
mild, moderate or severe) at the ﬁrst assessment (between 2
weeks to 3 months after MSC infusion) and ﬁnal follow-up
visits. Overall response was deﬁned as follows: CR was
deﬁned as the resolution of all clinical manifestations of
cGVHD in all the involved organs, except the irreversible
injury, or the scoring of all organs being zero. PR was
deﬁned as the global assessment improvement by at least
one point or at least a 50% improvement of clinical
manifestations but without CR, and with no worsening in
any domain. No response (NR) was deﬁned as no
improvement or deterioration of all affected organs.
Patients who experience early deaths due to GVHD prior
to assessment of response were considered NR as well.
Mixed response (MR) was deﬁned as improvement in at
least one organ with deterioration in another organ or
emergence of newly involved manifestation. Patients with
an improvement but later worsening were considered to
have PD as well. The response rate including CR and PR,
and no response was deﬁned as NR and PD. The OS rate
was calculated from the date of hematopoietic SCT to the
date of death or the last follow-up.
Flow-cytometric analysis
Flow cytometry was performed on a FACScan (Becton
Dickinson) (BDIS) equipped with a 15mW air-cooled
argon laser tuned at 488nm. Data acquisition and analysis
were performed by the CellQuest (Becton Dickinson)
(BDIS) research software.
Statistical analysis
The Kaplan–Meier method was used to estimate OS and
signiﬁcance of differences with the log-rank test (Mantel–
Cox). The proportion of lymphocyte subsets was compared
using a two-sided Wilcoxon signed ranks test. P-values
o0.05 were considered statistically signiﬁcant. Analysis
was performed with the SPSS software package (SPSS 13.0,
Inc., Chicago, IL, USA).
Results
Clinical characteristics
Nineteen patients with refractory cGVHD received MSC
transfusions based on the primary immunosuppressive
therapy. All patients except one were heavily pretreated
with immunosuppressive treatment more than 6 weeks
before the ﬁrst MSC transfusion, including CsA or FK506
(n¼17), steroids (n¼18), MMF (n¼5), MTX (n¼6),
penicillamine (n¼3), azathioprine (n¼2), thalidomide
(n¼2) and budesonide (n¼1). The characteristics of the
patients with cGVHD are listed in Table 1. Sixteen patients
were progressing during the immunosuppressive agents
taper, two patients showed no response after 2 months of
initiation and one relapsed when discontinued immuno-
suppressive therapy for 6 months. Eleven patients had
de novo, ﬁve had a progressive and three had the quiescent
form of cGVHD. cGVHD was diagnosed at a median of
160 days (range, 73–352) after transplantation. According
to NIH classiﬁcation, 14 patients (73.7%) were classiﬁed as
severe grade and 5 patients (26.3%) as moderate grade. Of
18 patients (94.7%) with skin involvement, three had severe
sclerotic features with a skin scoring of 3 in all areas tested,
and with decreased range of motion in at least one joint or
ulceration at the same time. The remainder had lichen
planus-like features, poikiloderma and maculopapular
changes involving the majority of their body surface.
Fourteen of the 17 cases of cGVHD of eyes were
keratoconjunctivitis sicca (Schirmer test o5mm/5min).
Among them, two patients had severe impairment with loss
of vision and were unable to work because of ocular
symptoms. Oral cGVHD was severe in six of sixteen
patients (84.2%). The major symptoms and signs were pain
with ulcer or mucositis, lichen, hyperkeratotic plaques,
xerostomia, pseudomembranes and mucocele. Eleven
patients with liver cGVHD (57.9%) had elevations of
serum alanine transaminase, alkaline phosphatase and
bilirubin. In patients with gastrointestinal (GI) involvement
(n¼10, 53%), eight had nausea, vomiting and abdominal
pain. One had diarrhea and one had strictures of the
esophagus. Other cGVHDs were those of the muscle and
joint (n¼3), thrombocytopenia (n¼2) and lung (n¼1).
Histological information was available for ﬁve of the
nineteen patients with cGVHD. No infusion-related
toxicity was observed during or immediately after the
administration of MSCs.
Primary response to therapy
According to different patients, the primary assessment was
carried out from 2 weeks to 3 months after the ﬁrst MSC
transfusion. A total of 8 patients (42.1%) had response
after the ﬁrst dose of MSC infusion. Eleven patients
showed no response. The median time from the ﬁrst MSC
infusion to meaningful improvement was 29 days (range,
1–100 days). Skin was the organ that was the most involved
(n¼18) and had 50% CR/PR rate. Two of three patients
with severe sclerodermatosis had minor PRs after the ﬁrst
MSC infusion. Responses were also seen in patients with
refractory cGVHD of oral mucosa (n¼15, 93.8%), GI
tract (n¼9, 90%), liver (n¼7, 63.6%) and eye (n¼2,
11.1%). No meaningful response was seen in the patients
with muscle or joint, lung or platelet involvement at the
ﬁrst follow-up.
Overall response to therapy
After the ﬁrst MSC administration, 11 patients received at
least two doses because of NR (n¼9) or consolidation
(n¼2). The median period from the ﬁrst to the second
infusion was 188 days (range, 13–944). The data are
summarized in Table 2. After the median follow-up time of
Novel treatment of chronic GVHD
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Bone Marrow Transplantation697 days (range, 81–1294), a total of 14 patients (73.7%)
had an overall response (CR, n¼4; PR, n¼10). The
median duration from the ﬁrst MSC transfusion to the best
response was 233 days (range, 81–761 days). The cumula-
tive response rate of skin was 78% (n¼14, CR¼4,
GPR¼1, PR¼9). Out of three patients with scleroderma,
one had a PR, one had a minor PR and the remaining one
had no response to the MSC infusion. The cumulative
response rate of eyes was 44.4% (n¼8) and three patients
with conjunctivitis achieved CR. Keratoconjunctivitis sicca
developed in 14 patients, and only 5 patients (35.7%)
showed amelioration of clinical symptoms but without
improvement in Schirmer’s test. Cumulative response was
also seen in oral mucosa (n¼16, 100%), liver (n¼10,
90.9%) and GI tract (n¼9, 90%). Of three patients with
moderate joint stiffness or myositis, two of them had a
delayed PR more than 7 months later. Two patients
with thrombocytopenia showed delayed responses at days
223 and 366 after multiple MSC infusions. The patient
(UPN206111) with lung involvement had no response to
MSC treatment and died of invasive fungal infection at 81
days after MSC infusion. The other three patients achieved
mixed response because of developing lung cGVHD after
MSC infusion, although their initial involved lesions were
improved.
Survival and immunosuppressive therapy
In this study, ﬁve patients (26.3%) died after the ﬁrst MSC
infusion. Their median survival duration was 183 days
(range, 61–805 days). Reasons for death were invasive
fungal infection (n¼2), primary malignant disease relapse
(n¼2) and bronchiolitis obliterans (n¼1), and the latter
was related to cGVHD. As yet, no surviving patient has
experienced relapse of the malignant disease at the median
follow-up duration of 669 days (range, 226–1294 days). The
2-year probability of survival rate was the same in patients
with refractory cGVHD administered MSCs (77.7%) and
in the 14 cases without refractory cGVHD (68.8%)
(P¼0.547). All of the patients of these two groups had
the same age, sex, primary diseases, treatment and the
grade of initial cGVHD (data not shown). But the median
times between cGVHD diagnoses to discontinuation of
immunosuppressive agents were 611 (337–1112) days and
427 (295–764) days in the refractory group and non-
refractory group, respectively. In the non-refractory group,
58.8% of the patients were able to discontinue immuno-
suppressive agents at the median time of 427 days and with
a stable CR duration of more than 375 days.
At the ﬁnal follow-up visit, ten out of fourteen surviving
patients (CR¼4, PR¼7, MR¼2, NR¼1) were able to
taper and/or discontinue their immunosuppressive therapy
after MSC transfusion (Table 2). Four patients with CR
and one with PR (UNP102309) who was suspected to have
post-transplantation lymphoproliferative disorder discon-
tinued immunosuppressive agents within 324 days (range,
200–550 days) after the ﬁrst MSC infusion, and maintained
continuous CR or stable disease for 675 days (range,
317–1198 days). Five patients with PR began to taper
(decreasing) immunotherapy at a mean time of 233 days
(range, 136–345 days) after the ﬁrst MSC infusion and
maintained improvement or were stable for a mean of 464
days (range, 90–842 days). The dose of prednisone was
successfully discontinued or reduced to no more than
0.1mg/kg in those responding patients during the whole
observation period. One NR and one PR patient main-
tained their basic therapies without needing further
escalation of immunosuppressive agents after the ﬁrst
MSC infusion, and two MR patients were retreated with
steroid 0.4mg/kg daily. Patient UPN124732 only accepted
MSC infusion and achieved a CR without further
immunosuppressive therapy.
Unfortunately, three patients developed lung involvement
during the tapering period or after withdrawal of immuno-
suppressive therapy at 6 months after MSC infusion, although
improvements in their oral mucosa, skin, eye or liver function
were reported. These patients were regarded as MR. Two
patients with PR who progressed to lung involvement were
retreated with prednisone 0.3–0.5mg/kg, and maintained
stable disease. The NR patient died of bronchiolitis obliterans
on day 816 after the ﬁrst MSC infusion, although tacrolimus
was combined with four times MSC.
No response was seen in two patients; one patient died
from invasive fungus disease on day 81 after the ﬁrst MSC
infusion; and one alive patient (UPN 065877) had severe
skin, esophagus and eye involvement, had received
immunosuppressive agents for more than 6 years and did
not respond to MSC treatment that was given twice.
Lymphocyte subset analysis
Flow cytometry was performed to detect lymphocyte
subsets pre- and post-MSC infusion. There were no
signiﬁcant changes in the proportion of T cells, B cells,
NK cells and activation in NR patient post-MSC
treatment. In the responsed group, the lymphocyte
(35.45±11.45% vs 25.32±11.15%, Po0.0001) and
CD3þCD4þ T cells (45.08±13.71% vs 39.15±11.99%,
P¼0.001) increased signiﬁcantly 3 months after MSC
transfusion, and the CD3þCD8þ T cells (45.13±16.53%
vs 50.06±18.02%, P¼0.018) decreased. However, the
proportion of CD4þCD25þ T cells and CD8þCD25þ
T cells did not change signiﬁcantly post-MSC transfusion
compared with pre-MSC infusion in patients with response
(the P-value was 0.493 and 0.327, respectively). The
CD8þCD28þ T cells decreased when the cGVHD
improved (42.42±15.33% vs 38.87±17.09%, P¼0.023)
and CD8þCD28  T cells increased (58.87±15.27% vs
63.31±16.65%, P¼0.025) post-MSC infusion. In addi-
tion, the CD5þCD19þ B cell subset increased
(29.42±15.33% vs 40.99±17.20%, P¼0.033) and
CD5 CD19þ B cells decreased (70.58±15.33% vs
59.01%±17.20%, P¼0.033) after MSC infusion in the
responsive group.
Discussion
cGVHD, a multi-organ disorder, is the major cause of late
non-relapse mortality after allogeneic hematopoietic SCT.
More than one-third of cGVHD patients do not respond to
ﬁrst-line therapy comprising corticosteroid and calcineurin
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4 and their prognosis is often
poor.
31 There is no standard second-line or salvage therapy
for these patients. Recent reports have described the use of
various therapies
5–11 for refractory cGVHD, but the results
have demonstrated limited efﬁcacy and low long-term
survival due to toxicity. MSCs are multipotent non-
hematopoietic stem cells that can differentiate into various
tissues,
13 repair injured tissues
12,14–17 and modulate allo-
geneic immunoreactions.
18,19,32 Recently, MSCs have been
used for the prophylaxis of acute GVHD
20 and the
treatment of patients with steroid-refractory acute GVHD,
at a dose of 1.0 10
6/kg per patient weight.
21–24 However,
there are few data regarding the efﬁcacy and safety of MSC
for cGVHD. There is only one published report that
demonstrated a temporary response of MSC in one patient
with liver cGVHD.
22
This is the pilot study of MSCs combined with initiation
of immunosuppressive therapies for refractory cGVHD, in
heavily pretreated patients who have exceeded 6 months of
treatment. A total of 14 patients (73.7%) had either CR
(n¼4) or PR (n¼10) and 71.4% of surviving patients were
able to discontinue or taper immunosuppressive agents
after MSC infusion. In addition, the 2-year survival rate
(77.7%) was greater than those of previous reports.
5,31
MSCs seemed to be more promising and effective for
cGVHD of the oral mucosa, GI ﬂuid, liver and skin
involvement. Depending on the responding organs, the
manifestations of the oral mucosa, GI ﬂuid and liver tended
to improve within 24h or a few weeks after the initiation of
MSC treatment, whereas it might take a long time for the
eyes and sclerotic lesion to achieve response. As we know,
damage to certain organs by cGVHD is not reversible or
curable. Interestingly, in the results of the present study, we
found that two patients (UPN102309 and UPN 152529)
with severe scleroderma had a PR or a minor PR. We also
noticed that in patients with keratoconjunctivitis sicca
(Schirmer’s test o5mm/5min) in this study, although
Schirmer’s test had not improved, their clinical symptoms
showed improvement by way of reduction in eyedrops
and pain. Therefore, some ‘irreversible’ damages of
chronic GVHD may be improved after MSC infusion.
Owing to the long duration required to attain a response,
patience should be exercised. The results of the present
study indicate that MSCs might be ineffective in cases with
bronchiolitis obliterans or may develop to bronchiolitis
obliterans.
In more than half of the patients, a single dose of MSC
was able to create a temporary or continuing response,
whereas some patients needed several doses to generate a
lasting response. On the contrary, despite several MSC
transfusions, no response or mixed response was seen in a
few patients. Clinical beneﬁt might not require sustained
engraftment of many MSCs, but could possibly result from
production of growth factors or temporary immunosup-
pression. MSC transfusion by the venous system is
distributed to different organs and tissues according to
the blood ﬂow.
33–35 Thus, MSCs may disperse to the oral
mucosa, GI ﬂuid and liver, which have an abundant blood
supply, repair the injured tissues and modulate immunor-
eaction. In vivo differentiation of transplanted MSCs into
non-immunosuppressive cells in a short time appears to be
one of the factors responsible for the temporary responses
seen in some patients.
36
To study the possible mechanism, we detected the
lymphocyte subsets to assess whether MSCs might parti-
cipate in the amelioration of GVHD. In our study, we did
not observe any signiﬁcant change in the CD4þCD25þ
T-cell subset accompanied by the improvement of cGVHD,
but found T lymphocyte subsets of CD8þCD28þ cells,
which served as active CTLs that participated in trans-
plantation immunity and rejection reaction, and were
down-regulated, accompanied by clinical remission,
whereas the proportion of CD8þCD28  cells were
increased. CD8þCD28  T cells, namely T-suppressor
cells, are MHC class I restricted and operate in an
Ag-dependent manner.
37 CD8þCD28  T cells served as
regulated cells to induce immune tolerance, inhibited the
function of APCs and thus controlled further activation of
T-helper cells and inhibited Ab production.
38,39 We also
found that B1 cells (CD5þCD19þ) increased and B2 cells
(CD5 CD19þ) decreased. The involvement of B cells in
the pathogenesis of cGVHD is well known. However,
recently, knowledge regarding the function of B1 cells was
renewed, and they were found to protect from autoimmu-
nity by producing cytokines such as IL-10.
40 Balances
of CD8þCD28 /CD8þCD28þ T cells and CD5þ
CD19þ/CD5-CD19þB cells may be involved in the
pathogenesis of cGVHD, but more immunological studies
speciﬁcally addressing this issue are needed to be performed
to conﬁrm this conjecture.
In summary, MSCs derived from BM might be a safe and
effective salvage treatment for patients with refractory
chronic GVHD who do not respond to corticosteroids and
other immunosuppressive therapies. MSCs in combination
with systemic immunosuppressive agents may improve
survival rates in patients with refractory cGVHD. The
small number of cases investigated in this study might not
provide more deﬁnitive conclusions, and, therefore, further
large-scale randomized clinical studies are needed to
compare this treatment with more conventional ap-
proaches. In addition, the number of infusions needed,
the optimum dose of cells in each infusion, the mechanism
of MSC treatment and the possible interactions of cells
with other drugs for chronic GVHD require further
investigation.
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